HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alberto sales

This article was originally published in The Rose Sheet

Executive Summary

Alberto-Culver will consider acquiring Keri Lotion from Bristol-Myers Squibb and has made its interest known, President and CEO Howard Bernick states during a Jan. 27 fiscal first quarter sales and earnings (ended Dec. 31) analyst call. Bernick has been eyeing Keri as a fit with Alberto's portfolio for a number of years. However, it is anticipated BMS will sell the U.S. and Canadian Consumer Medicines business as one unit, in which case Bernick says he hopes the potential buyer may be looking to shed Keri. First quarter sales, up 10.8% to $848 mil., were driven by consumer products (up 9.4% to $303.7 mil.) and beauty supply distribution (up 12.1% to $550.8 mil.), the firm reports. Net earnings were $51.9 mil., up 21.2%, excluding a $2.5 mil. non-cash charge related to the company's stock conversion. Including charges in both the year ago and current period, net earnings were $49.4 mil., compared to $1.7 mil. a year ago...

You may also be interested in...



Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

Big Data Offers International Benefits

The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.

UsernamePublicRestriction

Register

RS012775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel